Our bodies fight cancer every day, repairing DNA and cleaning out suspicious cells. But sometimes our powerful immune systems need help. That’s the concept of immunotherapy.
Three years ago, the ideas long dreamed of by cancer researchers were quickly taking shape, and Xconomy convened scientists, investors, entrepreneurs, and others in Seattle to take stock of the moment. Since then, there have been some clinical trial successes, some failures, and a growing number of companies large and small in the U.S. and abroad unveiling their own experimental approaches to cancer immunotherapy.
We’re gathering in Seattle again for another assessment of the field, and with a growing body of clinical and real-world data in hand, the prospects for patients. Join us on June 14 at the Fred Hutchinson Cancer Research Center for “What’s Hot In Cancer Immunotherapy 2017.” We’re still finalizing the speaker list, but previous speakers at our Seattle events have included:
Hans Bishop, CEO, Juno Therapeutics
Ira Mellman, VP, Cancer Immunology, Genentech
David Baker, Head of the Institute for Protein Design, University of Washington
Heather Franklin, CEO, Blaze Bioscience
Leen Kawas, CEO, M3 Biotechnology
Gary Gilliland, President and Director, Fred Hutchinson Cancer Research Center
Lee Hood, President, The Institute for Systems Biology
Thong Le, CEO, Accelerator
Matt Mcllwain, Managing Director, Madrona Venture Group
Bob Nelsen, Co-founder and Managing Director, ARCH Venture Partners
We’ll have more details to share soon, but in the meantime, you can save your spot by registering here.
